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The Mixed Lineage Leukemia (MLL) gene is
essential for embryonic hematopoietic stem
cell (HSC) development, but its role during adult
hematopoiesis is unknown. Using an inducible
knockout model, we demonstrate that Mll is
essential for the maintenance of adult HSCs
and progenitors, with fatal bone marrow failure
occurring within 3 weeks of Mll deletion. Mll-
deficient cells are selectively lost from mixed
bone marrow chimeras, demonstrating their
failure to self-renew even in an intact bone
marrow environment. Surprisingly, HSCs lack-
ingMll exhibit ectopic cell-cycle entry, resulting
in the depletion of quiescent HSCs. In contrast,
Mll deletion in myelo-erythroid progenitors
results in reduced proliferation and reduced
response to cytokine-induced cell-cycle entry.
Committed lymphoid and myeloid cells no
longer requireMll, defining the early multipotent
stages of hematopoiesis as Mll dependent.
These studies demonstrate thatMll plays selec-
tiveand independent roleswithin the hematopoi-
etic system, maintaining quiescence in HSCs
and promoting proliferation in progenitors.
INTRODUCTION
To maintain the adult hematopoietic system, an ongoing
and flexible interplay between lineage-instructive tran-
scription factors and epigenetic regulators is likely to
play a central role in determining appropriate numbers of
each cell type. Several sequence-specific transcriptional
regulators have been shown to play important roles in
hematopoiesis, but the role of chromatin-modifying epige-
netic regulators in this process is less clear. Polycomb
(PcG) and trithorax (trxG) family proteins first identified
in Drosophila melanogaster influence target gene ex-
pression in a manner that is heritable through multiple
daughter cell divisions (Cavalli and Paro, 1998; Cavalli324 Cell Stem Cell 1, 324–337, September 2007 ª2007 Elsevieand Paro, 1999), making these proteins uniquely qualified
to influence cell identity and plasticity during development
or to regenerate tissues such as the hematopoietic
system.
The Mixed Lineage Leukemia (MLL) gene was the first
trxG gene identified as a proto-oncogene (Djabali et al.,
1993; Domer et al., 1993; Gu et al., 1992; Tkachuk et al.,
1992). Chromosomal translocations disrupting the MLL
gene are primarily associated with acute lymphocytic
(ALL) or myelogenous leukemia (AML) of infants, as well as
secondary AML, accounting for more than 70% of each
these two groups (reviewed in Biondi et al., 2000; Pui and
Relling, 2000). MLL fusion genes produced by chromo-
somal translocation encode proteins composed of the N-
terminal1/3ofMLL fused tooneofover50 identified trans-
location partners. The expression of MLL fusion proteins
can influence lineage fidelity within the hematopoietic
system (Drynan et al., 2005) and can produce cells with
mixed lineage identity in human leukemia (Armstrong
et al., 2002).
Retroviral expression of MLL fusion proteins in bone
marrow cells is sufficient to produce AML or ALL in the
mouse, as is the expression of MLL fusions by knockin
or cre-mediated de novo chromosomal translocation
(Ayton and Cleary, 2001; Daser and Rabbitts, 2005). The
retroviral transduction model enabled structure-function
assays that identified motifs within the MLL N terminus
and the fusion partner that are essential for transforma-
tion. Collectively, such experiments indicate that MLL
fusion proteins act via a gain-of-function mechanism
through the acquisition of ectopic transactivation or
dimerization capacity (reviewed in Ayton and Cleary,
2001). TheN-terminal portion ofMLL is likely to play a large
role in targeting the fusion proteins to many of the same
loci regulated by endogenous MLL, as fusion proteins
have been shown by chromatin immunoprecipitation
(ChIP) to localize to at least some of the same regulatory
sequences as full-length wild-type MLL (Milne et al.,
2005; Xia et al., 2005) and increase expression of those
target genes (Horton et al., 2005).
Recent advances in purifying native MLL and com-
plexes from cell lines have yielded important insights
into themechanism bywhichMLL acts on its target genes.
Such complexes harbor histone methylation, acetylation,r Inc.
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Nakamura et al., 2002; Wysocka et al., 2005; Yokoyama
et al., 2004). The Su(var)3-9/Enhancer of zeste/Trithorax
(SET) domain at the extreme C terminus of MLL methyl-
ates histone H3 at lysine 4 (H3 K4), a modification associ-
ated with active transcription (Santos-Rosa et al., 2002).
Consistent components of these complexes include
WDR5, ASH2L, and menin. WDR5 and ASH2L interact
with the C-terminal SET domain, acting as cofactors for
the histone methyltransferase activity (Dou et al., 2006;
Steward et al., 2006). Menin interacts with the MLL N
terminus and bridges MLL to the basal transcriptional
machinery (Yokoyama et al., 2004). The interaction of
menin with the N terminus of MLL is important for main-
taining expression of an endogenous MLL target gene
in HeLa cells and is essential for transformation by MLL
fusion proteins (Yokoyama et al., 2004, 2005). Other pro-
teins have been described as part of the MLL complex,
or as transient interactors, but scant in vivo data are
available to validate the biological importance of these
interactions.
To understand the mechanisms by which MLL fusion
proteins are leukemogenic, it is critical to determine the
normal function of MLL in vivo, particularly in the cell types
that may represent the target for transformation by MLL
oncogenes. Several groups have disrupted the Mll gene
by different strategies, and in most cases, homozygous
Mll mutants die during embryogenesis (Ayton et al.,
2001; Yagi et al., 1998; Yu et al., 1995). Interestingly, the
deletion of the SET domain alone is not lethal, but homo-
zygous mutants exhibit mild loss-of-function phenotypes,
including homeotic transformation and reduced expres-
sion of several Hox genes (Terranova et al., 2006).
Due to the embryonic lethality of most Mll mutants,
studies aimed at identifying the role of Mll in the hema-
topoietic system have focused on embryonic hemato-
poiesis. Experiments using Mll-deficient embryonic stem
(ES) cells demonstrated that these cells were incapable
of differentiating into any hematopoietic cell types in
adult animals or in the fetal liver. This multilineage block
was due to the lack of HSCs in Mll-deficient embryos
as measured functionally (Ernst et al., 2004a). Using
an in vitro system, we showed that the block in
hematopoietic development was accompanied by global
reduction in Hox gene expression and could be rescued
by the reintroduction of individual Hox genes (Ernst
et al., 2004b). These experiments indicate that Mll plays
an essential role in the development of definitive HSCs
during embryogenesis and suggest that this is due to
global Hox gene misexpression. However, the early
and severe nature of the block in hematopoietic devel-
opment precluded a detailed analysis of the mecha-
nisms underlying the lack of HSCs or the assessment
of Mll function in more differentiated hematopoietic line-
ages. To address these questions, we developed a
mouse model in which Mll can be inducibly inactivated
in the bone marrow and in specific lineages to
provide a model system in which such functions could
be studied in more detail.Cell SRESULTS
Excision ofMll Exons 3 and 4 Generates
a Loss-of-Function Allele
To create an inducible loss-of-function model for Mll, we
designed an in-frame deletion to remove the AT hooks,
nuclear targeting sequences (NTS), and subnuclear local-
ization (SNL) sequences by flanking exons 3 and 4 with
loxP sites (‘‘floxed,’’ MllF). Thus, cre recombinase-medi-
ated excision produces an intragenic deletion (MllDN),
resulting in an MLL mutant protein lacking several NTS
and other interaction motifs (Figure 1A). We recently intro-
duced this allele into ES cells in combination with a strong
loss-of-function allele (Mll-lacZ) and found that these cells
exhibited a block in hematopoietic development (Ernst
et al., 2004a) and a block in embryoid body hematopoiesis
(Ernst et al., 2004b). Embryos homozygous for the MllDN
allele died in utero at embryonic day 12.5, one day later
in embryo development than MllDN/Mll-lacZ and two
days later than Mll-lacZ homozygotes (Figure S1 in the
Supplemental Data available with this article online).
MllDN/+ animals exhibit normal viability and fertility and
can be backcrossed to the C57Bl/6 strain without loss of
heterozygote viability, in contrast to the exon 3 insertion
Mll-lacZ strain (Yu et al., 1995). Thus, both the age of
embryonic lethality and the hematopoietic phenotypes
indicate that theMllDN allele is a strong hypomorphic allele
of Mll, slightly less severe than the Mll-lacZ allele.
To confirm the predicted subcellular distribution of the
MLLDN protein, we expressed an N- and C-terminally
tagged version of the predicted protein encoded byMllDN
in 293T cells. MLL is processed by proteolytic cleavage to
produce N- and C-terminal polypeptides that associate
with each other within a large protein complex (Hsieh
et al., 2003; Yokoyama et al., 2002). To determine the
localization of both protein fragments, cells transfected
with tagged wild-type and MLLDN constructs were visual-
ized by fluorescence microscopy using antibodies to the
N- and C-terminal tags, as well as an internal MLL anti-
body that recognizes an epitope in the N-terminal
fragment. MLLDN was clearly excluded from the nucleus
as determined by the N-terminal anti-Flag or anti-MLL
antibodies, as well as the C-terminal anti-HA antibody
(Figure 1B). In contrast, the full-length protein was exclu-
sively nuclear as expected (Figures 1B and 1C). This sub-
cellular localization was also observed with antibodies
that detect the endogenous MLLDN protein produced by
cre-mediated Mll excision in MllF/F bone marrow-derived
macrophages (Figure 1C). Western blot analysis demon-
strated similar levels of the MLLDN protein compared to
wild-type (data not shown).
To independently assess the function of the MLLDN
protein, we examined the expression of Hoxa7, Hoxa9,
and Hoxa10, well-characterized MLL target genes, in
MllDN/DN hematopoietic cells. As shown in Figure 1D, we
observed a progressive reduction (2- to 50-fold) in
Hoxa7, Hoxa9, and Hoxa10 expression between days 6
and 11 after cre-mediated excision of Mll. Other Hox
genes, such as Hoxb3, were not affected by Mll losstem Cell 1, 324–337, September 2007 ª2007 Elsevier Inc. 325
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MLL Function during Adult HematopoiesisFigure 1. The MllDN Allele Encodes a Cytoplasmic Protein with Reduced Activity
(A) Diagram of wild-type MLL with the deletion of sequences encoded by exons 3 and 4 indicated by dashed lines. Homology motifs are shown as
colored bars with the following indicated: AT hooks, minor groove DNA binding motif; SNL1 and 2, subnuclear targeting motif; NTS1 and 3, nuclear
targeting signals; MT, DNA methyltransferase homology and CpG binding motif; PHD, plant homeodomain homology regions; T, taspase cleavage
sites; AD, activation domain; and SET, Su(var)3-9/Enhancer of zeste/Trithorax homology region.
(B) Localization of tagged transfected wild-type MLL versus MLLDN. 293T cells were transfected with the construct labeled on the right of the panels
and stained with antibodies indicated at the left. Examples shown are representative of three independent experiments.
(C) Subcellular localization of endogenous MLL in wild-type (upper panels) and MllDN/DN macrophages (lower panels) derived in vitro from bone
marrow cells.
(D) Relative Hox gene expression levels were determined by quantitative PCR using linneg/low bone marrow cells isolated the days indicated afterMll
deletion. Each bar represents the average expression level from at least three animals. Error bars represent the standard deviation of the average
relative expression among animals. The asterisk denotes an undetectable Ct.(Figure S2). Furthermore, highly purified c-Kit+/
lineageneg/low/Sca-1+ (KLS) cells exhibited a similar fold
reduction inHoxa gene expression (Figure S3). Thus, exci-
sion ofMll exons 3 and 4 results in the production of a sta-326 Cell Stem Cell 1, 324–337, September 2007 ª2007 Elsevible protein that fails to become imported into the nucleus
and, based on the genetic, biochemical, and gene expres-
sion data above, results in a nonfunctional protein and
a loss-of-function phenotype.er Inc.
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MLL Function during Adult HematopoiesisFigure 2. Mll Maintains Bone Marrow Homeostasis
(A) Average bonemarrow cellularity per two hindlimbs as a function of time after the first pI:pC injection. Control animals (blue,Mll+/+) represent pI:pC-
injectedMx1-cre;Mll+/+, andMllDN/DN animals (red) represent pI:pC-injected Mx1-cre;MllF/F animals. Error bars represent 95% confidence intervals.
(B and C) Hematoxylin and eosin-stained sections from the humerus of control (B) orMx1-cre;MllF/F (C) animals 15 days after pI:pC injection. Slides
were imaged at 1003 and insets at 4003 magnification.Acute Mll Loss Results in Rapid
Bone Marrow Failure
To determine the role of Mll during adult steady-state
hematopoiesis, we employed an inducible transgenic
cre mouse strain (Mx1-cre; Kuhn et al., 1995). Control
and Mx1-cre;MllF/F animals were subjected to a brief se-
ries of polyinosinic:polycytidylic acid (pI:pC) injections to
induce cre-mediated excision of Mll in the bone marrow.
Prior to pI:pC injection, bone marrow populations did
not differ between control and Mx1-cre;MllF/F animals
(Figure S4). As early as 4 days after the first pI:pC injection,
nearly all bone marrow cells had undergone cre-mediated
excision (Figure S5). Approximately 19 days after inducing
cre expression, animals in which 80% or more of the bone
marrow expressed theMllDN allele exhibited bone marrow
cytopenia and died or had to be sacrificed (Figure 2). TheCellbone marrow of the few Mx1-cre;MllF/F animals surviving
the pI:pC injections was invariably composed of cells
that had not undergone cre-mediated Mll excision (data
not shown). Mx1-cre;MllF/F pI:pC-injected animals that
were also injected with wild-type bone marrow cells
were healthy beyond 6 months (data not shown), demon-
strating that the cause of death was from bone marrow
failure.
The Maintenance of Adult HSCs Requires
Continuous MLL Function
We previously demonstrated that MLL was essential for
the development of HSCs in the embryo, so we first deter-
mined whether acute loss of Mll affected the HSC-
enriched KSL population in the bone marrow. Phenotypic
and functional analyses were performed from day 4 afterStem Cell 1, 324–337, September 2007 ª2007 Elsevier Inc. 327
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MLL Function during Adult HematopoiesisFigure 3. Loss of HSCs uponMllDeletion
(A) Total KSL cell number per two hindlimbs of
control (Mx1-cre;Mll+/+ or MllF/F, blue) or Mx1-
cre;MllF/F (red) animals over a 2 week time
course. Inset graph shows the results of com-
petitive transplantation assays with 10,000
purified KSL cells to engraft lethally irradiated
recipients. The donor cells were purified from
Mll+/+ (blue) or MllDN/DN (red) bone marrow
from animals 8 days after pI:pC treatment.
For sorting details, see Figure S6. Peripheral
blood contribution was determined 3 weeks
after transplantation.
(B) Percentage of Ly5.1 (donor) peripheral
blood leukocytes (PBLs) in lethally irradiated
recipients transplanted with control (blue) or
MllDN/DN (red) unfractionated bone marrow
cells from animals as described in (A). Donor
cells were harvested at day 4 after pI:pC injec-
tion and were mixed with an equal number of
wild-type Ly5.2 carrier cells.
(C) Donor contribution as in (B) using a 10:1
ratio of donor to carrier cells to engraft irradi-
ated recipients. In both experiments, 3 3 105
wild-type carrier cells were used. For each
set of experiments, 2–4 individual donors and
4–12 recipients were analyzed.cre-mediated Mll deletion until the point at which Mx1-
cre;MllF/F animals died. Notably, the number of KSL cells
dropped precipitously and failed to recover (Figure 3A).
To determine whether the reduction in KSL cells reflected
a cell-intrinsic defect, we performed competitive trans-
plantation experiments with sorted pooled cells from the
day 8 time point. We injected up to 10,000 viable KSL cells
purified by fluorescence-activated cell sorting (FACS)
from pI:pC-treated Mx1-cre;MllF/F or control animals into
lethally irradiated recipients. Animals injected with wild-
type KSL cells all exhibited donor-derived cells in the
peripheral blood; however, MllDN/DN KSL cells failed to
yield any significant donor contribution as early as 3weeks
after transplantation (Figure 3A, inset) or as late as
20 weeks (data not shown).
To determine whether HSC activity was present inde-
pendent of the cell-surface phenotype, unfractionated
MllDN/DN bone marrow cells were tested in competitive
transplantation experiments. We tested either equal
numbers (1:1) or a 10-fold excess (10:1) of MllDN/DN bone
marrow mixed with wild-type bone marrow cells (Figures
3B and 3C). Remarkably, even a 10-fold excess of
MllDN/DN cells yielded recipients that were engrafted ex-
clusively by wild-type cells (Figure 3C). Thus, Mll deletion
results in the rapid decline in a phenotypically-defined
HSC-enriched population and loss of HSC activity from
this population and, in fact, from the bone marrow in
general.328 Cell Stem Cell 1, 324–337, September 2007 ª2007 ElsevieConsequences ofMll Deletion on HSC Viability
and Proliferation
One explanation for the inability of MllDN/DN KSL to com-
pete with wild-type cells in transplantation experiments,
as well as their disappearance from conditional knockout
bone marrow, is that cells undergo programmed cell
death in response to Mll deletion. In fact, an Mx1-cre-
induced knockout of the antiapoptoticMcl-1 gene exhibits
very similar kinetics of bone marrow cytopenia and HSC
loss (Opferman et al., 2005). To determine whether cell
death occurs in response to Mll loss, we assessed
Annexin V and propidium iodide (PI) staining of KSL cells
throughout the time course after Mll deletion. As shown
in Figure 4A, we found no significant difference in the
proportion of Annexin V+ KSL cells at any time point.
Annexin V+ cells were detectable in other populations in
the bonemarrow, but there were no significant differences
between the two genotypes in any population tested, nor
was there a difference in the overall viability (PI+) at early
time points (day 0–11, data not shown).
Because programmed cell death did not account for the
engraftment and homeostasis defects identified in Mll-
deficient KSL cells, we considered growth arrest as an
alternative hypothesis. For these experiments, we
assessed the proportion of KSL cells in cycle by using
12 hr bromodeoxyuridine (BrdU) pulses (Figures 4B and
4C). Cell-surface staining was performed to identify KSL
cells followed by intracellular staining for BrdU detectionr Inc.
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MLL Function during Adult HematopoiesisFigure 4. Cell Death and Proliferation within the MllDN/DN KSL Population
(A) Control (blue) orMllDN/DN (red) cells were stained with lineage, c-Kit, and Sca-1 antibodies and Annexin V to assess cell death within the KSL pop-
ulation over time. The percentage of Annexin V+ cells within the KSL gated population is shown from individual animals with the average shown as
a bar. For gating examples, see Figure S6B and S6C. Control (blue) or MllDN/DN (red) cells were stained as above, fixed, and then stained with anti-
BrdU and 7-AAD. Data in (B) indicate the percentage of BrdU-positive KLS cells from at least three individual animals per time point with the error bars
representing 95% confidence intervals. Data in (C) represent the percentage of BrdU-negative KSL cells (G0/G1 gate, [D]).
(D) Representative FACS plots illustrating BrdU and 7-AAD staining of KSL cells 11 days post cre induction.
(E) Representative Hoechst/Pyronin staining of sorted KLS/CD48neg cells at day 4 post cre induction, and (F) compiled Hoechst/Pyronin results from
four individual animals per genotype based on the gates shown in (E). Similar results were obtained in at least three independent experiments.(identifying cells in S phase during the prior 12 hr). Surpris-
ingly, we found a significant increase in BrdU+ KSL cells in
MllDN/DN bone marrow starting at day 8 after Mll deletion,Cell Stbecoming more severe by day 13 (Figure 4B). Conversely,
there were almost no BrdU-negative cells in the MllDN/DN
KSL population from day 11 (Figures 4C and 4D). Weem Cell 1, 324–337, September 2007 ª2007 Elsevier Inc. 329
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MLL Function during Adult HematopoiesisFigure 5. Selective Attrition of MllDN/DN Cells from Mixed Bone Marrow Chimeras
(A) Percentage of donor-type cells (Ly5.1+) within total bone marrow of chimeras. Bone marrow chimeras were established by coinjecting equal num-
bers of Ly5.1 donor bone marrow cells (from eitherMx1-cre;Mll+/+ orMx1-cre;MllF/F donors) plus wild-type bone marrow and waiting >6 weeks until
stable engraftment. Chimeras were then injected four times with pI:pC, and complete excision ofMll was confirmed 2 weeks after the first injection.
(B) Percentage of donor cells (Ly5.1+) within the linneg/low/c-Kit+ gated population.
(C–E) Percentage of donor-derived PBLs gated on (C) B220 for B cells, (D) CD3 for T cells, and (E) Gr-1 for neutrophils. Blue diamonds, chimeras
generated with Mx1-cre;Mll+/+ cells, and red squares, chimeras generated with Mx1-cre;MllF/F cells. Error bars represent the standard deviation.further enriched HSCs from this population to examine the
proportion of quiescent (G0) cells by sorting CD48
neg/KSL
cells (Kiel et al., 2005). Four days after cre induction (prior
to the increase in S phase cells), we found that MllDN/DN
CD48neg/KSL cells consistently exhibited a shift from G0
to G1 relative to control cells (Figures 4E and 4F). There-
fore the first defect observed in MllDN/DN HSCs is the fail-
ure to maintain quiescence, followed shortly thereafter by
an increased number of cycling KSL cells. These data sug-
gest that the depletion of HSCs upon Mll loss is due to
their failure to self-renew and maintain a noncycling pop-
ulation of HSCs.
To determine whetherMllDN/DN HSCs and their progeny
are ultimately depleted in vivo due to a failure to self-
renew, we generated chimeric animals in which cotrans-
planted wild-type bone marrow supports long-term ani-
mal viability. Bone marrow chimeras were generated
with Ly5.2+ wild-type cells mixed with either Ly5.1+ Mx1-
cre;MllF/F or Ly5.1+ transgene-negative MllF/F cells. After
pI:pC treatment, the Mx1-cre;MllF/F (now MllDN/DN) cells
were selectively lost from chimeras (Figure 5). This loss
occurred first in the bone marrow, with the linneg/low/c-
Kit+ pool depleted of MllDN/DN cells by 6 weeks (Figures
5A and 5B), followed shortly after by a decline in MllDN/DN
neutrophils, B-, and T cells in the peripheral blood (Figures
5C–5E). Because whole bonemarrowwas transferred, the330 Cell Stem Cell 1, 324–337, September 2007 ª2007 Elseviefact that peripheral blood T- and B cells were not com-
pletely depleted (Figures 5C and 5D) likely reflects the
long half-life of these cells (>12 weeks; Forster and Rajew-
sky, 1990; Kondo et al., 1997), whereas the more rapid
and complete loss of MllDN/DN neutrophils (half-life of 1
to 2 days) reflects the complete exhaustion of MllDN/DN
HSCs. These data demonstrate that Mll-deficient HSCs
are completely depleted, even in a bone marrow environ-
ment that includes wild-type neighboring hematopoietic
cells and does not become cytopenic. However, these
data do not account for the rapid cell loss in pI:pC-injected
Mx1-cre;MllF/F animals (Figure 2A). To investigate this fur-
ther, we focused on the consequences of Mll deletion on
progenitor populations.
Mll Plays an Independent Role in Maintaining
Progenitor Pools
To determine whether lineage-committed progenitors
were also affected by the loss of MLL function, we ana-
lyzed representative myeloid and lymphoid progenitor
populations by cell-surface phenotype. We found that
the absolute number of common lymphocyte progenitors
(CLP), common myeloid progenitors (CMP), granulocyte-
macrophage progenitors (GMP), and megakaryocyte-
erythrocyte progenitors (MEP) was reduced 1.4- to 4-fold
by day 11 after Mll deletion (Figure 6A). This wasr Inc.
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MLL Function during Adult HematopoiesisFigure 6. Reduction in Lymphoid and Myeloid Progenitors upon Mll Deletion
(A) Average cell number per two hindlimbs at day 11 post cre induction for the indicated cell types: c-Kit+/lineageneg/low/Sca-1+, KLS; common
lymphocyte progenitors, CLP; common myeloid progenitors, CMP; granulocyte-megakaryocyte progenitors, GMP; and megakaryocyte-erythroid
progenitors, MEP. Averages are from three to four animals, and error bars represent 95% confidence intervals.
(B) Colonies per spleen (CFU-S8) produced from pI:pC-injected control (Mll
F/F, blue) or Mx1-cre;MllF/F donors (red). Donor cells (1 3 105) were
harvested from animals 4 days after cre induction. At least four donor animals and 16 irradiated recipients were used per genotype. Error bars
represent 95% confidence intervals.
(C and D) Representative spleens for Mll+/+ (C) or MllDN/DN (D) donor cells.
(E) CFU-preB frequency in linneg/low bone marrow. Control (MllF/F, blue) orMllDN/DN cells (red) were generated as in (B) but were enriched in linneg/low
cells, plated, and scored (see Experimental Procedures). Error bars represent 95% confidence intervals.
(F) CFU-C assay using bone marrow cells prepared as in (E) but anti-IL7Ra and -Sca-1 were included in the lineage mix. Cells from at least three
donors per genotype were plated in triplicate, and colonies were scored 7 days later. Represented are the averages from all replicates with error
bars indicating the 95% confidence interval of the averages. Megakaryocyte/erythroid, Meg/E; burst formation unit-erythroid, BFU-E; granulocyte,
G; macrophage, M; granulocyte/macrophage, GM; and granulocyte, erythroid, macrophage, megakaryocyte colony, GEMM.
(G) CFU-C assay using in vitro-producedMllDN/DN bone marrow cells. Linneg/low cells fromMll+/+ orMllF/F bone marrow were infected with a cre-IRES-
GFP retrovirus, and 5000 GFP+ cells were plated in methylcellulose in triplicate as described in (E). Error bars represent 95% confidence intervals.
(H) Linneg/low/IL7Ra/Sca-1 cells were enriched from control (MllF/F, blue) orMllDN/DN (red) samples prepared as in (F) from animals 11 days after cre
induction. Samples were cultured in liquid medium containing SCF, IL-3, and IL-6. Cells were pulsed for 1 hr with BrdU, harvested, and analyzed by
flow cytometry at the indicated time points, reflecting days of in vitro culture. Error bars represent 95% confidence intervals.
(I) Cells as described above were incubated with low serum and cytokine-free medium overnight, followed by readdition of serum and cytokines for
1 hr followed by BrdU pulses as in (H). Error bars represent 95% confidence intervals.predominantly due to an overall reduction in linneg/low/
c-Kit+ cells (3.8-fold, data not shown).
To examine progenitor frequencies prior to their pheno-
typic reduction, we subjected bone marrow from the day
6 time point to in vivo (colony-forming units-spleen day
8 [CFU-S8]) and in vitro (colony-forming unit-culture
[CFU-C]) clonal progenitor assays. Reduced myeloid, ery-Cell Sthroid, and lymphoid colony frequencies were observed
with MllDN/DN bone marrow samples (2- to 5-fold, Figures
6B–6F). The reduction in all colony types suggests a uni-
form requirement for Mll in the primitive hematopoietic
compartment.
The maintenance of progenitors in vivo may reflect an
intrinsic requirement for Mll within the progenitor pool ortem Cell 1, 324–337, September 2007 ª2007 Elsevier Inc. 331
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MLL Function during Adult HematopoiesisFigure 7. Mll Is Dispensable for Homeostasis of Lineage-Committed Cells and Is Not Compensated by Close Homologs in the
Primitive Hematopoietic Compartment
(A) Analysis of bonemarrow (top four panels) and peritoneal cells (bottom four panels) in lysozymeM-cre;MllF/+ (left column) and lysozymeM-cre;MllF/F
animals (right column). Inset in the lower four panels indicates F/480 expression on Mac-1/Gr-1 gated cells.
(B) Analysis of bone marrow cells of CD19-cre;MllF/+ (left column) and CD19-cre;MllF/F (right column) animals.
(C) Analysis of thymocytes in lck-cre;MllF/+ (left column) and lck-cre;MllF/F (right column) animals. The lower four panels represent CD4/CD8 gated
cells stained with the indicated antibodies. Two representative animals are shown for each strain.
(D–G) The expression ofMll homologs within purified hematopoietic populations. Quantitative real-time PCR results are shown forMll (Mll-1) (D),Mll-2
(E), Mll-3 (F), and Mll-4 (G). Populations are as described in Figure 6, with KSL cells further fractionated to enrich HSCs with short- and long-term
engrafting potential (Flt3+ and Flt3, respectively). Also tested are the populations predicted to be affected in the lineage-specific cre strains:332 Cell Stem Cell 1, 324–337, September 2007 ª2007 Elsevier Inc.
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distinguish between these possibilities, we excised Mll
in myelo-erythroid progenitors (linneg/low/Sca-1/IL-7Ra
cells) purified from MllF/F or Mll+/+ bone marrow and
determined CFU-C frequencies withMllDN/DN cells gener-
ated in vitro through retroviral introduction of cre recom-
binase. This approach also revealed 2-fold reduced
CFU-C from MllDN/DN myelo-erythroid progenitors, with
all colony types similarly reduced (Figure 6G). Together,
these data indicate that Mll is required for the mainte-
nance of myelo-erythroid progenitors through a cell-
intrinsic mechanism.
Proliferation Defects in MllDN/DN
Myelo-Erythroid Progenitors
To determine the basis for the functional and phenotypic
reduction inMllDN/DN progenitors, we assessed cell death
and proliferation. We found no significant difference be-
tween the viability of MllDN/DN cells in vivo or using the
in vitro cre excision strategy described above (data not
shown). We assessed proliferation in vitro by using
a pool of myelo-erythroid progenitors (linneg/low/IL7Ra/
c-Kit+/Sca-1 cells encompassing the CMP, GMP, and
MEP populations). Using a time course of in vitro BrdU
pulses, we found that MllDN/DN progenitors exhibited
reduced proliferation relative to controls (Figure 6H). In
addition, serum/cytokine starvation experiments demon-
strated that MllDN/DN progenitors exhibited a 2.6-fold re-
duction in cells that could re-enter the cell cycle upon se-
rum and cytokine restoration (Figure 6I). Importantly, the
composition of the cell populations before or after in vitro
culture was not significantly different between wild-type
andMllDN/DN populations (Figure S7 and data not shown).
Based on these results, we conclude thatMll is required to
sustain cytokine-driven proliferation of myelo-erythroid
progenitors. Thus, the combination of ectopic, nonrenew-
ing HSC proliferation in conjunction with the reduced pro-
liferation within the larger progenitor pool (linneg/low/c-Kit+)
is likely toplayamajor role in the rapid attritionof cells in the
pI:pC-injectedMx1-cre;MllF/F animals.
Differentiating T-, B-, andMyeloid Cells No Longer
Require Mll for Homeostasis
To determine whether Mll is continuously required
throughout the differentiation of myeloid and lymphoid
cells, we used lineage-specific cre transgenic or knockin
strains to deleteMll in cells subsequent to lineage commit-
ment. In contrast to the results withmore primitive progen-
itors, we found no difference in the steady-state number or
function of peripheral B cells, T cells, or macrophages and
neutrophils in CD19-cre, lck-cre, or lysozyme-M cre;MllF/F
animals, respectively (data not shown). We carefully ex-Cellamined the populations representing the beginning of
maximal cre expression in each strain and found that there
were no differences in cell number or phenotype despite
efficient gene deletion within the appropriate population
(Figures 7A–7C and data not shown). Thus, these data de-
lineate an early window of hematopoietic development as
Mll dependent, encompassing the stem and progenitor
pools. These data also demonstrate that our failure to de-
tect mature MllDN/DN leukocytes in transplanted animals
(Figures 3 and 5) was not due to a late block in T cell, B
cell, or granulocyte differentiation, and therefore accu-
rately reflect a defect in stem/progenitor function.
Due to the contrast of these results with the severe, mul-
tilineage phenotype observed in early progenitors, we
considered compensation by Mll homologs as an expla-
nation for the differential effect ofMll deletion on primitive
versus more mature, lineage-committed cell types. The
Mll homologsMll-2 through -4 exhibit similar domain orga-
nization and encode SET domains predicted to methylate
histone substrates with the same specificity (FitzGerald
and Diaz, 1999; Prasad et al., 1997; Ruault et al., 2002).
Mll-2, the most closely related homolog, is expressed in
a similar manner to Mll in the hematopoietic system (see
below). MLL-2 has been isolated in similar protein com-
plexes as MLL and has also been localized to the same
target gene by ChIP (Dou et al., 2005; Hughes et al., 2004;
Nakamura et al., 2002; Yokoyama et al., 2004). Mll-1, -2,
-3, and -4 are expressed in CD4+CD8+ thymocytes and
CD19+B220+ pro/pre B cells, which were analyzed in the
lck-cre and CD19-cre strains, respectively (Figures 7A–
7G and Figure S8). The overlap in expression ofMll homo-
logs illustrates the potential for compensatory functions
within in thesecell types; however,Mll-2and -3are alsoex-
pressed significantly within the KSL population and thus
would be equally capable to compensate for Mll-1 loss in
stem and progenitor populations, which is not the case.
These data demonstrate that the selective expression of
Mll homologs within the hematopoietic system cannot
account for the selective effects of Mll-1 loss shown in
this study. Despite the expression of Mll-2 and -3 within
stem and progenitor populations, Mll-1 performs an es-
sential and nonredundant role in maintaining HSCs and
progenitors (Figure 7H). In the more mature populations,
it is possible that the relatively high levels of Mll-2, -3,
and -4 compensate for Mll-1 loss, but a definitive test of
this hypothesis will require the analysis of compound
mutants.
DISCUSSION
The central finding of this study is that adult steady-state
hematopoiesis depends on Mll, based on essentialmyelomonocytic precursors (M, Mac-1+/Gr-1+), pro/pre-B cells (B, B220+/CD19+), and double-positive T cells (T, CD4+/CD8+). Results represent the
mean of triplicate reactions with all expression levels normalized toGapdh. Error bars indicate standard deviation, and asterisks indicate an undetect-
able Ct. Similar results were obtained in three independent experiments.
(H) Model illustrating the essential, nonredundant role of MLL in maintaining stem and progenitor cells. The green box encompasses cells affected by
MLL loss, with those outside the box unaffected at the level of steady-state cell numbers. Red boxes indicate point at which lineage-specific cre ex-
pression occurs using the strains shown.Stem Cell 1, 324–337, September 2007 ª2007 Elsevier Inc. 333
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genitor cells. In the absence ofMll, HSCs exit from aquies-
cent state and precociously undergo cell-cycle entry. Ec-
topic cycling of HSCs occurs without an increase in this
population and coincident with functional deficits, sug-
gesting that cell division in this compartment is accompa-
nied by differentiation and not self-renewal. In contrast,
the role ofMll within primitive myelo-erythroid progenitors
appears to be quite distinct, in that progenitor frequency is
reduced uponMll deletion through a mechanism involving
reduced proliferation. In conjunction with germline loss-
of-function analyses (Ernst et al., 2004a), the studies pre-
sented here demonstrate thatMll is necessary for both the
development and maintenance of HSCs. Further charac-
terization will reveal whether all of these MLL-dependent
processes utilize common or distinct molecular pathways.
Our data generally support the concept that MLL acts
on a selective set of target genes in different cell types.
Based on a genome-wide ChIP study in the U937 cell
line, it has been proposed that MLL functions as a tran-
scription start site-specific global transcriptional regulator
(Guenther et al., 2005). This conclusion is partly based on
the large overlap in Pol II and MLL localization at active
promoters. If this colocalization indicated a biologically
important association, one would expect a severe conse-
quence for all cells in which MLL activity is removed. This
prediction is difficult to reconcile with the selective pheno-
types observed in vivo upon Mll loss. For example, ES
cells and many differentiating tissues in chimeric animals
are unaffected byMll deficiency (Ernst et al., 2004a; Ernst
et al., 2004b). These observations, along with the results
presented in this study, suggest that selective and distinct
target genes are regulated byMLL and its homologs in dif-
ferent tissues.
The reduced proliferation of myelo-erythroid progeni-
tors shown in this study is consistent with previous obser-
vations using embryoid body-derived hematopoietic pro-
genitors. In these studies, the reduced expression of
multiple Hox genes appeared to be the primary cause
for the reduced colony frequency in Mll mutant embryoid
bodies (Ernst et al., 2004b). Thus, we predict that the re-
duced Hox gene expression in progenitors is similarly
likely to play a major role in reduced progenitor frequency
and proliferation upon Mll deletion. Conversely, Hoxa7
and Hoxa9 are consistently overexpressed in MLL fu-
sion-initiated leukemia in humans and in mouse models,
and are rate limiting for leukemogenesis or influential in
determining leukemic cell phenotype (Armstrong et al.,
2002; Ayton and Cleary, 2003; Kumar et al., 2004; So
et al., 2004). Based on the results of the current study
and results of Hox expression analyses in Mll loss- and
gain-of-function experiments (Ernst et al., 2004b; Horton
et al., 2005), we propose that alteredHox gene expression
may be responsible for the proliferation component of the
leukemogenic program induced by MLL fusion proteins.
The regulation of quiescence in HSCs is less likely to be
explained by Hox gene maintenance alone, based on
analyses of individual and compoundHox gene knockouts
in which such a phenotype has not been reported (Bijl334 Cell Stem Cell 1, 324–337, September 2007 ª2007 Elsevet al., 2006; Brun et al., 2004; Lawrence et al., 2005).
This suggests that there are other HSC-specificMll target
genes involved in this process. Such HSC-specific target
genes may remain activated by MLL fusion oncoproteins
as HSCs differentiate, resulting in the maintenance of
a self-renewal program coincident with a proliferation-
promoting program mediated by Hox gene overexpres-
sion. Candidate genes for this self-renewal program in-
clude those reported as reactivated in an MLL-AF9 leuke-
mia model (Krivtsov et al., 2006). Leukemia can be
initiated by introducing MLL fusion oncogenes into com-
mitted progenitors (Cozzio et al., 2003; Krivtsov et al.,
2006; Somervaille and Cleary, 2006), suggesting that the
reactivation of such a self-renewal program byMLL fusion
oncogenes can occur in progenitors. However, the intro-
duction of MLL fusion oncogenes into HSCs rather than
progenitorsmay facilitate fusion protein access to a quies-
cence-promoting gene expression program. One predic-
tion of this hypothesis is that the introduction ofMll fusions
into HSCs (rather than progenitors) would result in a more
persistent, chemotherapy-resistant pool of leukemic cells,
a concept that has not been tested in mouse models.
Importantly, our studies suggest that targeting MLL fu-
sion oncogenes through mechanisms that generally inter-
fere with MLL function may cause bone marrow failure.
Thus it will be essential to identify strategies that selec-
tively target MLL fusion oncoproteins without compromis-
ing wild-type MLL function. This effort will be aided by
a comprehensive assessment of target genes affected
by MLL fusions versus those affected by wild-type MLL.
EXPERIMENTAL PROCEDURES
Mice, Competitive Transplantation,
and CFU-S Assays
Animals were maintained in accord with the Dartmouth Animal
Resources Center and I.A.C.U.C. policies. Mll floxed alleles and ES
targeting have been described (Ernst et al., 2004a). To generateMllDN
animals, MllF/F animals were crossed to the EIIa-cre strain (Jackson
Labs). MllDN/DN embryos were generated by crossing heterozygotes.
Eight a.m. of the day of vaginal plug observation was considered
E 0.5. The MllF/F strain was backcrossed to C57Bl/6 for more than
nine generations then backcrossed to B6.SJL (Jackson Labs) for five
generations. Animals were crossed to the Mx1-cre, lysozyme M-cre,
CD19-cre (obtained from Drs. Rajewski and Orkin, Harvard Medical
School) and lck-cre strains (obtained from Dr. Wilson, University of
Washington) to produce homozygous Mll floxed (MllF/F), cre-express-
ing strains.Mx1-cre;MllF/F,Mx1-cre;Mll+/+, orMllF/F mice were treated
with two to four injections of pI:pC (GE Healthcare) every other day.
Two, three, or four injections were performed for the day 4, 6, or 8–
19 time points, respectively. Increasing the number of injections re-
sulted in a higher penetrance of the phenotypes described, without al-
tering the kinetics of their appearance. All animals were 6–12 weeks
old for analyses in this study. The following formula was used for the
pI:pC dose: (10 3 animal mass [g] + 50) mg pI:pC.
For competitive transplantation experiments, C57BL/6J recipients
were irradiated with a split dose of 1100 Rads 3 hr apart. Bone marrow
cells were prepared by crushing with a mortar and pestle in ice-cold
Hank’s buffered saline solution (HBSS) supplemented with 2% fetal
bovine serum (FBS). Red cells were removed with ACK lysis buffer
(0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM EDTA [pH 7.2]). Bone marrow
chimeras were generated by injecting a mixture of 1.25 3 106 donor
cells (Mx1-cre;MllF/F, MllF/F, or Mx1-cre; Mll+/+, Ly5.1) plus 2.5 3 105ier Inc.
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MLL Function during Adult Hematopoiesiscarrier cells (wild-type Ly5.2 or Ly5.1/5.2) and waiting >6 weeks for
stable engraftment. Animals weremaintained on sterile food and water
(containing 50 mg/mL Baytril) for 3 weeks after irradiation. For the
CFU-S8 assay, 1 3 10
5 bone marrow cells from animals receiving 2
pI:pC doses were injected into lethally irradiated recipients. Eight
days later, spleens were transferred to Tellesniczky’s fixative. Colonies
were counted and photographed with a Leica MZ7.5 dissecting micro-
scope fitted with a Cannon Powershot S3 IS digital camera.
Flow Cytometry, Annexin V Binding Assays,
and G0/G1 Analysis
Lineage staining was accomplished with unconjugated rat anti-CD4,
-CD3, -CD8, -Gr-1, -B220, -CD19, -Ter119, and -Mac-1 and for
some experiments anti-Sca-1 and -IL-7Ra (all antibodies were from
BD Biosciences except the IL7Ra [eBiosciences]). Lineage antibodies
were detected with goat ant-rat F(ab0)2 tricolor (Caltag), blocked with
rat serum (Sigma), and stained with anti-Sca-1 and -c-Kit antibodies
(BD Biosciences). Stained cells were incubated with Annexin V FITC
as described by the manufacturer and analyzed immediately with
a FACSCalibur (BD Biosciences) and FlowJo software (Treestar, Inc).
We first determined that Mx1-cre;Mll+/+ and MllF/F animals exhibited
indistinguishable levels of Annexin V and PI staining after pI:pC injec-
tion (data not shown) then used either genotype as controls for the
following experiments. Annexin V-positive controls were generated
for each analysis by incubating cells with 1 mM H2O2 at 37
C for
5 min. G0/G1 analysis was performed by first FACS purifying KLS/
CD48neg cells then incubating 10,000 sorted cells in 10 mg/mL Hoechst
33342 and 100 mM verapamil (both from Molecular Probes) for 45 min
at 37C. Samples were then supplemented to 2 mg/mL Pyronin Y
(Sigma), incubated for an additional 15 min, washed, and analyzed
immediately on a FACSAria (BD Biosciences). Anti-CD48 was from
BD Biosciences. The unpaired t test was used to evaluate the statisti-
cal significance of differences in G0 populations.
In Vivo Proliferation Assays
Mx1-cre;MllF/F, Mx1-cre;Mll+/+, or MllF/F mice were pI:pC injected as
described above. At 12 and 6 hr prior to sacrifice, animals were in-
jected with 1 mg BrdU. Cells were harvested and stained as described
above. Stained cells were then fixed, permeabilized, and incubated
with FITC-labeled anti-BrdU and 7-AAD per the manufacturer’s sug-
gestions (BD Biosciences).
Ex Vivo Introduction of Cre Recombinase
and In Vitro Progenitor Assays
Bone marrow cells were prepared from 6- to 8-week-old Mll+/+ and
MllF/F mice. Cells were stained with unlabeled antibodies as described
above and depleted with sheep anti-rat magnetic beads (Dynal).
Linneg/low cells were then resuspended in growth medium (IMDM con-
taining 20% FBS, 200 mM nonessential amino acids [NEAA], 200 mM
L-glutamine [L-gln], 100 U/ml penicillin G, 100 mg/ml streptomycin [P/
S], and 50 mM 2-ME) supplemented with 40 ng/ml IL-6, 20 ng/ml IL-3,
40 U/ml LIF, 80 ng/ml SCF, and 10 mg/ml polybrene. Spin infection was
performed for 30 min at 25C in 96-well plates. FACS-purified GFP+
cells were subjected to colony assays as described (Ernst et al.,
2004b). For the proliferation assays, linneg/low cells were enriched as
described above from Mx1-cre;MllF/F or MllF/F animals at day 11 post
cre induction. Cell densities were adjusted to 5 3 105 cells/mL in
growth medium supplemented with 1XBIT (StemCell Technologies),
50 ng/mL SCF, 10 ng/mL IL-3, and 10 ng/mL IL-6. Cells were incu-
bated with BrdU at 10 mM for 1 hr. For the starvation experiment, cells
were grown for 2 days, washed and incubated in cytokine-free, 0.5%
FBS growth medium overnight, shifted to complete medium, and then
pulsed with BrdU as described above. For the pre-B colony assay,
10,000 linneg/low cells were plated in Methocult M3630 (StemCell Tech-
nologies) supplemented with 100 ng/mL SCF, 20 ng/mL murine Flt3L,
and 10 ng/mL IL-7. Pre-B colonies were scored after 7 days. Cytokines
were from R&D Systems.Cell SReal-Time, Quantitative PCR
Total RNA from the sorted populations indicated in Figure 7 was puri-
fiedwith the RNeasyMini kit (QIAGEN). After extraction, 1 mgMS2 bac-
teriophage RNA (Roche) was added as a carrier, and mRNA was am-
plified with the RiboAmp RNA Amplification Kit (Arcturus) per the
manufacturer’s recommendations for one round of amplification.
Hox gene detection was performed as described (Ernst et al.,
2004b), and Mll family primer and probes are shown in Figure S5.
Relative expression levels were determined by using theDDCt method
(Livak and Schmittgen, 2001) with data from triplicate multiplexed
reactions normalized to Gapdh. Quantitative real-time PCR was
performed on a 7900HT machine using the 9600 emulation setting
(Applied Biosystems).
Histopathology
For bone marrow sections, the humerus was removed, cleaned, and
transferred to Bouin’s fixative overnight at 4C. Fixed samples were
sectioned and stained by the Harvard Histopathology Core Facility.
Samples were imaged on a Nikon Optiphot-2 microscope with 103
and 403 objectives.
Plasmids
The region spanning the exon 3 to 4 deletion (DN) was amplified by
PCR from MllDN/DN fibroblast RNA. This PCR product was inserted
into the FseI and PvuI sites of the human MLL cDNA. The resulting
MLLDN cDNA was modified to encode the Flag epitope at the 50 end
and the HA epitope at the 30 end by inserting annealed oligonucleo-
tides encoding the epitope sequence. The tagged cDNAs (wild-type
and MLLDN) were then subcloned into pCDNA3.1() (Invitrogen) at
the XhoI and EcoRV sites.
Cell Culture, Transfection, and Immunofluorescence
293T cells were maintained in DMEM supplemented with 10% FBS,
200 mM L-gln, P/S, and 100 nM NEAA and transfected with FuGENE
6 (Roche). Thirty-six hours posttransfection, cells were plated on cov-
erslips and grown overnight before fixing in 4% paraformaldehyde in
PBS for 5 min. Cells were then blocked with PBS containing 2%
goat serum and 0.2% Triton X-100 overnight. Anti-Flag M2 (1:100,
Sigma), anti-MLL1 (BL1290), and anti-HA (both 1:100, Bethyl Labs)
were incubated with coverslips for 30 min at room temperature, then
washed three times in PBS. Detection was performed with Alexa
Fluor-568 goat anti-mouse or Alexa Fluor-488 goat anti-rabbit (both
at 1:1000, Molecular Probes). Stained cells were then washed three
times in PBS, with the final wash containing 1mg/mL 40, 6-diamidino-
2-phenylindole (DAPI). Coverslips were mounted onto slides with Pro-
long Gold antifade medium (Molecular Probes). Images were captured
with a Zeiss AxioVisionZ1 microscope and analyzed in Adobe Photo-
shop. Macrophages were cytospun onto slides and stained as de-
scribed above.
Supplemental Data
Supplemental Data include eight figures and can be found with this
article online at http://www.cellstemcell.com/cgi/content/full/1/3/
324/DC1/.
ACKNOWLEDGMENTS
This study is dedicated to Stanley Korsmeyer, in whose lab the gener-
ation of the mouse model described here was initiated. This work was
supported by funds from the Sydney Kimmel and V Foundations,
NCRR COBRE grant #2P20RR016437, NIH #DK067119, and ACS
IRG#82-003-21. We acknowledge the insightful comments of David
Traver, Malek Djabali, and Iannis Aifantis. We are grateful for the gifts
of cre mice from Drs. Rajewsky and Orkin. We thank Hanno Hock for
essential advice on pI:pC vendors and Amy Wagers for advice on
the Hoechst/Pyronin staining. We thank GaryWard for expert cell sort-
ing, Nancy Speck and her laboratory members for helpful comments,tem Cell 1, 324–337, September 2007 ª2007 Elsevier Inc. 335
Cell Stem Cell
MLL Function during Adult HematopoiesisR. Mako Saito for help with microscopy, and Victor Ambros and labo-
ratory members for help with real-time PCR.
Received: February 8, 2007
Revised: April 15, 2007
Accepted: May 22, 2007
Published: September 12, 2007
REFERENCES
Armstrong, S.A., Staunton, J.E., Silverman, L.B., Pieters, R., den Boer,
M.L., Minden, M.D., Sallan, S.E., Lander, E.S., Golub, T.R., and Kors-
meyer, S.J. (2002). MLL translocations specify a distinct gene expres-
sion profile that distinguishes a unique leukemia. Nat. Genet. 30,
41–47.
Ayton, P.M., and Cleary, M.L. (2001). Molecular mechanisms of leuke-
mogenesis mediated by MLL fusion proteins. Oncogene 20, 5695–
5707.
Ayton, P.M., and Cleary, M.L. (2003). Transformation of myeloid pro-
genitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9.
Genes Dev. 17, 2298–2307.
Ayton, P., Sneddon, S.F., Palmer, D.B., Rosewell, I.R., Owen, M.J.,
Young, B., Presley, R., and Subramanian, V. (2001). Truncation of
the Mll gene in exon 5 by gene targeting leads to early preimplantation
lethality of homozygous embryos. Genesis 30, 201–212.
Bijl, J., Thompson, A., Ramirez-Solis, R., Krosl, J., Grier, D.G., Law-
rence, H.J., and Sauvageau, G. (2006). Analysis of HSC activity and
compensatory Hox gene expression profile in Hoxb cluster mutant
fetal liver cells. Blood 108, 116–122.
Biondi, A., Cimino, G., Pieters, R., and Pui, C.H. (2000). Biological and
therapeutic aspects of infant leukemia. Blood 96, 24–33.
Brun, A.C., Bjornsson, J.M., Magnusson, M., Larsson, N., Leveen, P.,
Ehinger, M., Nilsson, E., and Karlsson, S. (2004). Hoxb4-deficient mice
undergo normal hematopoietic development but exhibit amild prolifer-
ation defect in hematopoietic stem cells. Blood 103, 4126–4133.
Cavalli, G., and Paro, R. (1998). The Drosophila Fab-7 chromosomal
element conveys epigenetic inheritance during mitosis and meiosis.
Cell 93, 505–518.
Cavalli, G., and Paro, R. (1999). Epigenetic inheritance of active chro-
matin after removal of the main transactivator. Science 286, 955–958.
Cozzio, A., Passegue, E., Ayton, P.M., Karsunky, H., Cleary, M.L., and
Weissman, I.L. (2003). Similar MLL-associated leukemias arising from
self-renewing stem cells and short-lived myeloid progenitors. Genes
Dev. 17, 3029–3035.
Daser, A., and Rabbitts, T.H. (2005). The versatile mixed lineage
leukaemia gene MLL and its many associations in leukaemogenesis.
Semin. Cancer Biol. 15, 175–188.
Djabali, M., Selleri, L., Parry, P., Bower, M., Young, B., and Evans, G.A.
(1993). A trithorax-like gene is interrupted by chromosome 11q23
translocations in acute leukaemias. Nat. Genet. 4, 431.
Domer, P.H., Fakharzadeh, S.S., Chen, C.S., Jockel, J., Johansen, L.,
Silverman, G.A., Kersey, J.H., and Korsmeyer, S.J. (1993). Acute
mixed-lineage leukemia t(4;11)(q21;q23) generates anMLL-AF4 fusion
product. Proc. Natl. Acad. Sci. USA 90, 7884–7888.
Dou, Y., Milne, T.A., Tackett, A.J., Smith, E.R., Fukuda, A., Wysocka,
J., Allis, C.D., Chait, B.T., Hess, J.L., and Roeder, R.G. (2005). Physical
association and coordinate function of the H3 K4 methyltransferase
MLL1 and the H4 K16 acetyltransferase MOF. Cell 121, 873–885.
Dou, Y., Milne, T.A., Ruthenburg, A.J., Lee, S., Lee, J.W., Verdine, G.L.,
Allis, C.D., and Roeder, R.G. (2006). Regulation of MLL1 H3K4 methyl-
transferase activity by its core components. Nat. Struct. Mol. Biol. 13,
713–719.
Drynan, L.F., Pannell, R., Forster, A., Chan, N.M., Cano, F., Daser, A.,
and Rabbitts, T.H. (2005). Mll fusions generated by Cre-loxP-mediated336 Cell Stem Cell 1, 324–337, September 2007 ª2007 Elsevde novo translocations can induce lineage reassignment in tumorigen-
esis. EMBO J. 24, 3136–3146.
Ernst, P., Fisher, J.K., Avery, W., Wade, S., Foy, D., and Korsmeyer,
S.J. (2004a). Definitive hematopoiesis requires the mixed-lineage leu-
kemia gene. Dev. Cell 6, 437–443.
Ernst, P., Mabon, M., Davidson, A.J., Zon, L.I., and Korsmeyer, S.J.
(2004b). An Mll-dependent Hox program drives hematopoietic pro-
genitor expansion. Curr. Biol. 14, 2063–2069.
FitzGerald, K.T., and Diaz, M.O. (1999). MLL2: a new mammalian
member of the trx/MLL family of genes. Genomics 59, 187–192.
Forster, I., and Rajewsky, K. (1990). The bulk of the peripheral B-cell
pool in mice is stable and not rapidly renewed from the bone marrow.
Proc. Natl. Acad. Sci. USA 87, 4781–4784.
Gu, Y., Nakamura, T., Alder, H., Prasad, R., Canaani, O., Cimino, G.,
Croce, C.M., and Canaani, E. (1992). The t(4;11) chromosome translo-
cation of human acute leukemias fuses the ALL-1 gene, related to Dro-
sophila trithorax, to the AF-4 gene. Cell 71, 701–708.
Guenther, M.G., Jenner, R.G., Chevalier, B., Nakamura, T., Croce,
C.M., Canaani, E., and Young, R.A. (2005). Global and Hox-specific
roles for the MLL1 methyltransferase. Proc. Natl. Acad. Sci. USA
102, 8603–8608.
Horton, S.J., Grier, D.G., McGonigle, G.J., Thompson, A., Morrow, M.,
De Silva, I., Moulding, D.A., Kioussis, D., Lappin, T.R., Brady, H.J., and
Williams, O. (2005). Continuous MLL-ENL expression is necessary to
establish a ‘‘Hox Code’’ andmaintain immortalization of hematopoietic
progenitor cells. Cancer Res. 65, 9245–9252.
Hsieh, J.J., Ernst, P., Erdjument-Bromage, H., Tempst, P., and Kors-
meyer, S.J. (2003). Proteolytic cleavage of MLL generates a complex
of N- and C-terminal fragments that confers protein stability and sub-
nuclear localization. Mol. Cell. Biol. 23, 186–194.
Hughes, C.M., Rozenblatt-Rosen, O., Milne, T.A., Copeland, T.D.,
Levine, S.S., Lee, J.C., Hayes, D.N., Shanmugam, K.S., Bhattacharjee,
A., Biondi, C.A., et al. (2004). Menin associates with a trithorax family
histone methyltransferase complex and with the hoxc8 locus. Mol.
Cell 13, 587–597.
Kiel, M.J., Yilmaz, O.H., Iwashita, T., Yilmaz, O.H., Terhorst, C., and
Morrison, S.J. (2005). SLAM family receptors distinguish hematopoi-
etic stem and progenitor cells and reveal endothelial niches for stem
cells. Cell 121, 1109–1121.
Kondo, M., Weissman, I.L., and Akashi, K. (1997). Identification of
clonogenic common lymphoid progenitors in mouse bone marrow.
Cell 91, 661–672.
Krivtsov, A.V., Twomey, D., Feng, Z., Stubbs, M.C., Wang, Y., Faber,
J., Levine, J.E., Wang, J., Hahn, W.C., Gilliland, D.G., et al. (2006).
Transformation from committed progenitor to leukaemia stem cell ini-
tiated by MLL-AF9. Nature 442, 818–822.
Kuhn, R., Schwenk, F., Aguet, M., and Rajewsky, K. (1995). Inducible
gene targeting in mice. Science 269, 1427–1429.
Kumar, A.R., Hudson, W.A., Chen, W., Nishiuchi, R., Yao, Q., and Ker-
sey, J.H. (2004). Hoxa9 influences the phenotype but not the incidence
of Mll-AF9 fusion gene leukemia. Blood 103, 1823–1828.
Lawrence, H.J., Christensen, J., Fong, S., Hu, Y.L., Weissman, I., Sau-
vageau, G., Humphries, R.K., and Largman, C. (2005). Loss of expres-
sion of the Hoxa-9 homeobox gene impairs the proliferation and repo-
pulating ability of hematopoietic stem cells. Blood 106, 3988–3994.
Livak, K.J., and Schmittgen, T.D. (2001). Analysis of relative gene
expression data using real-time quantitative PCR and the 2(-Delta
Delta C(T)). Methods 25, 402–408.
Milne, T.A., Briggs, S.D., Brock, H.W., Martin, M.E., Gibbs, D., Allis,
C.D., and Hess, J.L. (2002). MLL targets SET domain methyltransfer-
ase activity to Hox gene promoters. Mol. Cell 10, 1107–1117.
Milne, T.A., Martin, M.E., Brock, H.W., Slany, R.K., and Hess, J.L.
(2005). Leukemogenic MLL fusion proteins bind across a broad regionier Inc.
Cell Stem Cell
MLL Function during Adult Hematopoiesisof the Hox a9 locus, promoting transcription andmultiple histone mod-
ifications. Cancer Res. 65, 11367–11374.
Nakamura, T., Mori, T., Tada, S., Krajewski, W., Rozovskaia, T., Was-
sell, R., Dubois, G., Mazo, A., Croce, C.M., and Canaani, E. (2002).
ALL-1 is a histone methyltransferase that assembles a supercomplex
of proteins involved in transcriptional regulation. Mol. Cell 10, 1119–
1128.
Opferman, J.T., Iwasaki, H., Ong, C.C., Suh, H., Mizuno, S., Akashi, K.,
and Korsmeyer, S.J. (2005). Obligate role of anti-apoptotic MCL-1 in
the survival of hematopoietic stem cells. Science 307, 1101–1104.
Prasad, R., Zhadanov, A.B., Sedkov, Y., Bullrich, F., Druck, T., Ralla-
palli, R., Yano, T., Alder, H., Croce, C.M., Huebner, K., et al. (1997).
Structure and expression pattern of human ALR, a novel gene with
strong homology to ALL-1 involved in acute leukemia and to Drosoph-
ila trithorax. Oncogene 15, 549–560.
Pui, C.H., and Relling, M.V. (2000). Topoisomerase II inhibitor-related
acute myeloid leukaemia. Br. J. Haematol. 109, 13–23.
Ruault, M., Brun, M.E., Ventura, M., Roizes, G., and De Sario, A. (2002).
MLL3, a new human member of the TRX/MLL gene family, maps to
7q36, a chromosome region frequently deleted in myeloid leukaemia.
Gene 284, 73–81.
Santos-Rosa, H., Schneider, R., Bannister, A.J., Sherriff, J., Bernstein,
B.E., Emre, N.C., Schreiber, S.L., Mellor, J., and Kouzarides, T. (2002).
Active genes are tri-methylated at K4 of histone H3. Nature 419, 407–
411.
So, C.W., Karsunky, H., Wong, P., Weissman, I.L., and Cleary, M.L.
(2004). Leukemic transformation of hematopoietic progenitors by
MLL-GAS7 in the absence of Hoxa7 or Hoxa9. Blood 103, 3192–3199.
Somervaille, T.C., and Cleary, M.L. (2006). Identification and charac-
terization of leukemia stem cells in murine MLL-AF9 acute myeloid leu-
kemia. Cancer Cell 10, 257–268.
Steward, M.M., Lee, J.S., O’Donovan, A., Wyatt, M., Bernstein, B.E.,
and Shilatifard, A. (2006). Molecular regulation of H3K4 trimethylation
by ASH2L, a shared subunit of MLL complexes. Nat. Struct. Mol. Biol.
13, 852–854.Cell StTerranova, R., Agherbi, H., Boned, A., Meresse, S., and Djabali, M.
(2006). Histone and DNAmethylation defects at Hox genes in mice ex-
pressing a SET domain-truncated form of Mll. Proc. Natl. Acad. Sci.
USA 103, 6629–6634.
Tkachuk, D.C., Kohler, S., andCleary,M.L. (1992). Involvement of a ho-
molog of Drosophila trithorax by 11q23 chromosomal translocations in
acute leukemias. Cell 71, 691–700.
Wysocka, J., Swigut, T., Milne, T.A., Dou, Y., Zhang, X., Burlingame,
A.L., Roeder, R.G., Brivanlou, A.H., and Allis, C.D. (2005). WDR5 asso-
ciates with histone H3 methylated at K4 and is essential for H3 K4
methylation and vertebrate development. Cell 121, 859–872.
Xia, Z.B., Popovic, R., Chen, J., Theisler, C., Stuart, T., Santillan, D.A.,
Erfurth, F., Diaz, M.O., and Zeleznik-Le, N.J. (2005). The MLL fusion
gene, MLL-AF4, regulates cyclin-dependent kinase inhibitor CDKN1B
(p27kip1) expression. Proc. Natl. Acad. Sci. USA 102, 14028–14033.
Yagi, H., Deguchi, K., Aono, A., Tani, Y., Kishimoto, T., and Komori, T.
(1998). Growth disturbance in fetal liver hematopoiesis of Mll-mutant
mice. Blood 92, 108–117.
Yokoyama, A., Kitabayashi, I., Ayton, P.M., Cleary, M.L., and Ohki, M.
(2002). Leukemia proto-oncoprotein MLL is proteolytically processed
into 2 fragments with opposite transcriptional properties. Blood 100,
3710–3718.
Yokoyama, A., Wang, Z., Wysocka, J., Sanyal, M., Aufiero, D.J., Kita-
bayashi, I., Herr, W., and Cleary, M.L. (2004). Leukemia proto-onco-
protein MLL forms a SET1-like histone methyltransferase complex
with menin to regulate Hox gene expression. Mol. Cell. Biol. 24,
5639–5649.
Yokoyama, A., Somervaille, T.C., Smith, K.S., Rozenblatt-Rosen, O.,
Meyerson, M., and Cleary, M.L. (2005). The menin tumor suppressor
protein is an essential oncogenic cofactor for MLL-associated leuke-
mogenesis. Cell 123, 207–218.
Yu, B.D., Hess, J.L., Horning, S.E., Brown, G.A., and Korsmeyer, S.J.
(1995). Altered Hox expression and segmental identity in Mll-mutant
mice. Nature 378, 505–508.em Cell 1, 324–337, September 2007 ª2007 Elsevier Inc. 337
